Inactivation of the Glucose-Dependent Insulinotropic Polypeptide Receptor Improves Outcomes following Experimental Myocardial Infarction-Reference-Cited by-同舟云学术

Inactivation of the Glucose-Dependent Insulinotropic Polypeptide Receptor Improves Outcomes following Experimental Myocardial Infarction

Published:2018-02 Issue:2 Volume:27 Page:450-460.e6
ISSN:1550-4131
Container-title:Cell Metabolism
language:en
Short-container-title:Cell Metabolism

Author:

Ussher John R.,Campbell Jonathan E.,Mulvihill Erin E.,Baggio Laurie L.,Bates Holly E.,McLean Brent A.,Gopal Keshav,Capozzi Megan,Yusta Bernardo,Cao Xiemin,Ali Safina,Kim Minsuk,Kabir M. Golam,Seino Yutaka,Suzuki Jinya,Drucker Daniel J.

Funder

Heart and Stroke Foundation

CIHR

Merck

Banting and Best Diabetes Centre

Novo Nordisk

Publisher

Elsevier BV

Subject

Cell Biology,Molecular Biology,Physiology

Reference41 articles.

1. Cardiomyocyte glucagon receptor signaling modulates outcomes in mice with experimental myocardial infarction;Ali;Mol. Metab.,2014

2. The gluco- and liporegulatory and vasodilatory effects of glucose-dependent insulinotropic polypeptide (GIP) are abolished by an antagonist of the human GIP receptor;Asmar;Diabetes,2017

3. Gipr is essential for adrenocortical steroidogenesis; however, corticosterone deficiency does not mediate the favorable metabolic phenotype of Gipr(-/-) mice;Bates;Diabetes,2012

4. Glucose-dependent insulinotropic polypeptide stimulates osteopontin expression in the vasculature via endothelin-1 and CREB;Berglund;Diabetes,2016

5. Pharmacology, physiology, and mechanisms of incretin hormone action;Campbell;Cell Metab.,2013

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integrated multi-omics analysis identifies features that predict human pluripotent stem cell-derived progenitor differentiation to cardiomyocytes;Journal of Molecular and Cellular Cardiology;2024-11

2. Investigational and emerging gastric inhibitory polypeptide (GIP) receptor-based therapies for the treatment of obesity;Expert Opinion on Investigational Drugs;2024-07-17

3. Lipoprotein lipase as a target for obesity/diabetes related cardiovascular disease;Journal of Pharmacy & Pharmaceutical Sciences;2024-07-16

4. Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide;Cardiovascular Diabetology;2024-07-10

5. The current landscape for diabetes treatment: Preventing diabetes-associated CV risk;Atherosclerosis;2024-07